US IPO Pipeline SEC S-1 Filings — August 24, 2026

24-08-2026

Serina Therapeutics, Inc. filed an S-1 registration statement with the SEC on August 24, 2026, to register up to 12,500,000 shares of common stock for resale by Roth Principal Investments under a committed equity facility. The company is a clinical-stage biotechnology firm focused on neurological diseases, with lead candidate SER-252 (POZ-apomorphine) for advanced Parkinson's disease, which received IND clearance in January 2026 and dosed its first patient in a Phase 1b SAD trial in February 2026. The filing does not disclose any financial results or period-over-period comparisons, so no positive or negative performance metrics are available.

• · The registration statement covers up to 12,500,000 shares of common stock for resale by Roth Principal Investments.
• · The committed equity facility allows Serina to sell up to $25,000,000 of common stock at its sole discretion over a 36-month period.
• · The per-share purchase price is based on VWAP with discounts of 7.0% (below $12.5M aggregate) or 3.0% (at or above $12.5M aggregate).
• · A threshold price of $0.50 per share applies for each purchase date.
• · The company's lead candidate SER-252 received IND clearance in January 2026 and first patient dosing in February 2026.

24-08-2026

Essential Minerals Acquisition Corp filed an S-1 registration statement for an IPO of 15,000,000 units at an assumed price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one Share Right (entitling the holder to one-tenth of a Class A share upon a business combination). The sponsor, Essential Minerals Sponsor LLC, initially invested $25,000 for 5,750,000 founder shares (Class B) at ~$0.004 per share, and will purchase 512,500 private placement units simultaneously. The company has no prior assets or operations and is a blank-check company formed to effect a merger or acquisition.

• · Founder shares are subject to a lock-up until the earlier of (i) six months after business combination or (ii) when Class A shares close at or above $12.00 for any 20 trading days within a 30-trading-day period.
• · Founder shares automatically convert to Class A shares on a one-for-one basis upon business combination, subject to anti-dilution adjustments to maintain the founder group's aggregate ownership at 25% of post-offering ordinary shares (excluding private placement shares and Share Rights).
• · Holders of Class B shares have exclusive voting rights on director appointment/removal and on continuing the company outside the Cayman Islands prior to the business combination.
• · If the company fails to complete a business combination within the required time, Share Rights will expire worthless and holders will receive no trust account proceeds.
• · The sponsor, officers, and directors have agreed to waive redemption rights on founder shares, private placement shares, and public shares in connection with the business combination and certain charter amendments.

24-08-2026

NEXTNRG, INC. filed an S-1 registration statement on August 24, 2026, to register the resale of up to 112,946,708 shares of common stock issuable upon conversion of Series C Preferred Stock. The company will not receive any proceeds from the resale, but it has already received approximately $7.2 million in gross proceeds from the initial sale of the preferred stock. However, the company faces significant liquidity challenges, with cash on hand of $4,481,795 as of August 21, 2026, expected to fund operations only through December 1, 2026, and current liabilities substantially exceeding current assets as of June 30, 2026.

• · The company is a 'smaller reporting company' and an 'emerging growth company' under the JOBS Act, allowing reduced disclosure obligations.
• · The company has elected to use the extended transition period for adopting new accounting standards.
• · The Series C Preferred Stock ranks senior to Common Stock, Series A Preferred Stock, and Series B Preferred Stock.
• · The conversion price is subject to full-ratchet anti-dilution adjustments, and the alternate conversion feature may increase the number of shares issued.
• · The company's principal business address is 407 Lincoln Road #9F, Miami Beach, FL 33139.
• · The company's common stock is listed on Nasdaq under the symbol 'NXXT'.

24-08-2026

Live Oak Acquisition Corp. VI, a Cayman Islands blank check company, filed an S-1 registration statement on August 24, 2026, for an initial public offering of 20,000,000 units at $10.00 per unit, each consisting of one Class A ordinary share and one-half of one redeemable warrant, aiming to raise $200,000,000. The company has not yet identified a business combination target and will use the proceeds held in trust to acquire a business in any industry or geography. The sponsor purchased founder shares at a nominal price ($25,000 for 5,750,000 shares), creating immediate and substantial dilution for public shareholders, and the company warns that the sponsor could profit even if the target subsequently declines in value.

• · The company is incorporated in the Cayman Islands and classified as a blank check company (SIC 6770).
• · The warrants become exercisable 30 days after the initial business combination and expire five years after that combination.
• · Public shareholders have redemption rights upon completion of the initial business combination, but holders of more than 15% of the shares sold in the offering are restricted from redeeming more than 15% without the company's prior consent if a shareholder vote is held.
• · The sponsor's founder shares convert into Class A ordinary shares on a one-for-one basis, subject to anti-dilution adjustments that ensure the founder shares represent 20% of the total ordinary shares outstanding after the IPO and any business combination issuances.
• · Prior to the business combination, only holders of Class B ordinary shares have the right to appoint and remove directors and to vote on continuing the company outside the Cayman Islands.

24-08-2026

OHB Pediatrics Ltd. filed an S-4 registration statement with the SEC on August 24, 2026, in connection with a proposed business combination with RACC. The filing details the company's financial position, capital structure, and risk factors, including the potential for Nasdaq listing delays that could affect shareholder redemption rights. The transaction is subject to regulatory and shareholder approvals, with no specific financial performance metrics disclosed in this filing.

• · The S-4 filing was made on August 24, 2026, under Registration No. 333-.
• · Shareholders may not receive timely notification of Nasdaq listing approval before the redemption deadline or extraordinary general meeting.
• · The filing includes detailed capital structure information for both OHB Pediatrics Ltd. and RACC, covering multiple classes of common and preferred stock.

24-08-2026

Polar Power, Inc. filed an S-1 registration statement on August 24, 2026, covering the potential resale of up to 8,488,774 shares of common stock by selling stockholders, which is more than double the current outstanding shares of 4,211,564. The company recently elected two new independent directors, Jim Ahern and Menachem Shalom, to fill board vacancies. However, the company faces significant risks, including non-compliance with Nasdaq's minimum stockholders' equity requirement (only ~$0.1 million reported as of Dec 31, 2025) and a highly dilutive capital structure with variable-rate convertible notes and preferred stock that could further depress the stock price.

• · The company received a Nasdaq deficiency letter on May 1, 2026 for non-compliance with the $2.5 million minimum stockholders' equity requirement, reporting only ~$0.1 million in equity.
• · Nasdaq granted an extension until October 28, 2026 to regain compliance, with specific reporting requirements.
• · The company effected a 1-for-7 reverse stock split in 2025 and may seek another reverse split to maintain listing.
• · The convertible notes and Series A Preferred have variable conversion prices that decline as the stock price declines, creating a potentially dilutive spiral.
• · The selling stockholders include entities that received shares via convertible notes, warrants, preferred stock conversion, and a consulting agreement.
• · The company will not receive any proceeds from the sale of shares by selling stockholders, except potentially from cash exercise of warrants.